Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) approved inducement stock options covering 240,135 shares of common stock for 20 newly hired, non-executive employees on Aug. 20, 2026. Granted under the Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), the options carry an $8.99 exercise price, equal to Iovance's closing share price on the grant date. Each award vests over three years, with one-third vesting on the first anniversary of the employee's start date and the remainder in eight quarterly installments over the following two years, subject to continued employment. Iovance develops polyclonal tumor-infiltrating lymphocyte therapies, including Amtagvi (lifileucel), an FDA-approved one-time treatment for previously treated advanced melanoma that is available at more than 95 authorized treatment centers and approved in three global markets.